Better Therapeutics Inc (BTTX) Peer Comparison

$0.00

$-0.01 (-99.15%)

As on 29-Jan-2025 15:00EDT

Market cap

$0 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

2.3

Div. Yield

0 %

Edit

	Better Therapeutics Inc (BTTX)	Neurobo Pharmaceuticals Inc (NRBO)	Histogen (HSTO)
Market cap ($ Mln)	0	20	0
Revenue ($ Mln)	--	--	0
Net Profit ($ Mln)	-31.57	-27.73	-12.40
Net Margin (%)	--	-693,325.00	-65,278.95
RoE (%)	--	-240.85	-147.67
Price to Earnings	--	--	--
Price-To-Book	2.29	1.32	0.02

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Better Therapeutics Inc (BTTX)	Neurobo Pharmaceuticals Inc (NRBO)	Histogen (HSTO)
Operating Revenue	0.00	0.00	0.02
Cost of Revenue	3.11	0.03	0.18
Gross Profit	-2.73	-0.03	3.77
Operating Expenses	29.61	11.42	12.07
Operating Profit (EBIT)	-29.61	-19.63	-12.06
Other Income	0.00	--	0.00
Profit before Tax	-31.56	-13.97	-12.38
Provision for Tax	0.01	-7.85	0.00
Profit after Tax (Net Income)	-31.57	-6.12	-12.40
Minority Interest	0.00	--	0.01
Consolidated Profit	-23.94	-15.28	-7.15

Liabilities ($ Mln)

	Better Therapeutics Inc (BTTX)	Neurobo Pharmaceuticals Inc (NRBO)	Histogen (HSTO)
Shareholder's Funds	-9.94	21.75	5.44
Minority Interest	0.00	--	0.01
Non-Current Liabilities	7.72	0.71	0.07
Current Liabilities	12.94	11.78	1.35
Total Liabilities	22.94	33.53	19.07

Assets ($ Mln)

	Better Therapeutics Inc (BTTX)	Neurobo Pharmaceuticals Inc (NRBO)	Histogen (HSTO)
Non-Current Assets	3.38	0.00	0.36
Current Assets	7.35	33.53	5.46
Total Assets	22.94	33.53	19.07
Total Debt*	14.31	0.07	0.00
Net Current Assets	-5.59	21.75	4.11

Cashflow ($ Mln)

	Better Therapeutics Inc (BTTX)	Neurobo Pharmaceuticals Inc (NRBO)	Histogen (HSTO)
Cash From Operating Activities	-28.93	-11.71	-9.68
Cash Flow from Investing Activities	-1.18	-0.59	-0.22
Cash from Financing Activities	5.28	0.03	3.32
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	Better Therapeutics Inc (BTTX)	Neurobo Pharmaceuticals Inc (NRBO)	Histogen (HSTO)
ROCE (%)	-132.08	-33.58	-46.61
ROE (%)	-221.99	-33.65	-147.67
ROA (%)	-103.19	-24.30	-80.67
EBIT Margin (%)	--	--	-65,168.42
Net Margin (%)	--	--	-65,278.95
Cash Profit Margin (%)	--	--	-0.47

Growth Ratios

	Better Therapeutics Inc (BTTX)	Neurobo Pharmaceuticals Inc (NRBO)	Histogen (HSTO)
Revenue Growth (%)	--	--	-99.50
EBIT Growth (%)	24.06	--	-14.30
Net Profit Growth (%)	30.16	59.83	-14.92
EPS Growth (%)	43.11	--	--
Book Value Growth (%)	-184.34	--	--

Valuation Ratios

	Better Therapeutics Inc (BTTX)	Neurobo Pharmaceuticals Inc (NRBO)	Histogen (HSTO)
Price / Earnings	-0.66	--	--
Price / Book Value	-29.19	--	--
Dividend Yield (%)	--	--	--
EV/EBITDA	-0.71	2.93	0.75
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	Better Therapeutics Inc (BTTX)	Neurobo Pharmaceuticals Inc (NRBO)	Histogen (HSTO)
Debt to Equity	-0.78	0.00	0.00
Short term debt to equity ratio	-0.66	0.00	0.00
Current Ratio	0.57	2.85	4.05
Quick Ratio	0.57	--	4.05
Interest Coverage	-15.18	-5.21	-4,127.00

Operating Efficiency Ratios

	Better Therapeutics Inc (BTTX)	Neurobo Pharmaceuticals Inc (NRBO)	Histogen (HSTO)
Debtors to sales (%)	--	--	0.00
Asset Turnover	0.00	0.00	0.00
Receivable days	--	--	12.79
Inventory Days	--	--	2,774.60
Payable days	305.02	10,031.33	2,315.42
Cash Conversion Cycle	--	--	471.96

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly